Disclosed are calcium-sensing receptor antagonist compounds of Formula (I), salts thereof, and methods of their preparation. The compounds of Formula (I) contain indanyl moieties. Specific examples of compounds of Formula (I) include: 3-{ 2-[(1R)-1-{ [(2R)-3-{ [1-(2, 3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino} -2-hydroxypropyl]oxy} ethyl]phenyl} propanoic acid, 3-{ 2-[1(1R)-1-{ [(2R)-3-{ [1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino} -2-hydroxypropyl]oxy} ethyl]-6-fluorophenyl)propanoic acid, and 3-{ 2-[(1R)-1-{ [(2R)-3-{ [1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino} -2-hydroxypropyl]oxy} ethyl]-5-fluorophenyl} propanoic acid. The compounds are useful for treating disorders associated with abnormal bone or mineral homeostasis such as hypoparathyroidism, osteosarcoma, periodontitis, bone fracture healing, deformative arthritis, rheumatoid arthritis, Pagets disease, humoral hypercalcemia syndrome associated with malignant tumour and bone fracture healing or osteoporosis.
